Eastern Time SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced positive topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

东部时间圣地亚哥，2024年3月12日（环球通讯社）--Crinetics Pharmaceuticals，Inc.（纳斯达克：CRNX）是一家临床阶段的制药公司，专注于内分泌疾病和内分泌相关肿瘤的新型治疗方法的发现，开发和商业化，今天宣布了其开放标签的帕洛司汀2期类癌综合征研究的阳性结果，一种口服，每日一次的研究化合物，用于治疗肢端肥大症和类癌综合征。

“We are very pleased that these results from our Phase 2 study of paltusotine in carcinoid syndrome confirm our decision to move expeditiously toward Phase 3,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “These results highlight the potential of paltusotine to deliver significant benefits to patients living with the debilitating symptoms of carcinoid syndrome.

Crinetics创始人兼首席执行官斯科特·斯特拉瑟斯（ScottStruthers）博士说：“我们非常高兴，我们对类癌综合征中帕妥司汀的第二阶段研究结果证实了我们迅速进入第三阶段的决定。”。“这些结果突显了帕妥斯汀对患有类癌综合征衰弱症状的患者产生重大益处的潜力。

We plan to engage with the FDA to align on a Phase 3 study design and have begun preparations to enable the initiation of a Phase 3 program by the end of the year.” Key Highlights from the Phase 2 Study: The Phase 2 trial was a randomized, open-label, parallel group, multi-center study evaluating the safety, tolerability, pharmacokinetics, and efficacy of paltusotine in people living with carcinoid syndrome.

我们计划与FDA合作，调整第三阶段研究设计，并已开始准备，以便在年底前启动第三阶段计划。”第二阶段研究的关键亮点：第二阶段试验是一项随机，开放标签，平行组，多中心研究，评估了帕妥斯汀在类癌综合征患者中的安全性，耐受性，药代动力学和疗效。

A total of 36 participants were randomized to receive either 40 mg (n=18) or 80 mg (n=18) of paltusotine for 8 weeks, with the .

共有36名参与者被随机分配接受40 mg（n=18）或80 mg（n=18）的帕洛司汀治疗8周。